For the quarter ending 2026-03-31, OGN had $542M increase in cash & cash equivalents over the period. $188M in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 146 | -205 | 160 | 145 |
| Depreciation | 39 | 46 | 40 | 36 |
| Amortization | 47 | 50 | 52 | 53 |
| Impairment of assets | - | 0 | 0 | 9 |
| Acquired in-process research and development and milestones | 0 | 0 | 0 | 0 |
| Accretion and changes in fair value in contingent consideration | 5 | 41 | 32 | -12 |
| Deferred income tax expense (benefit) | 3 | 30 | 40 | 10 |
| Stock-based compensation | 19 | 7 | 24 | 22 |
| Unrealized foreign exchange loss (gain) | -3 | 13 | 9 | -16 |
| Gain on debt repurchase | - | 27 | 0 | 46 |
| Impairment of goodwill | - | 301 | - | - |
| Gain on sale of jada | 81 | - | - | - |
| Other Noncash Income Expense | -12 | -27 | -16 | -24 |
| Accounts receivable | 65 | -160 | 5 | -9 |
| Inventories | 9 | -81 | 63 | 34 |
| Other current assets | 15 | -22 | -24 | 67 |
| Trade accounts payable | 32 | -120 | 12 | 40 |
| Accrued and other current liabilities | 95 | -156 | 73 | -98 |
| Income taxes payable | -4 | -31 | -76 | 8 |
| Increase Decrease In Other Operating Capital Net | -8 | -10 | -8 | -81 |
| Net cash flows provided by operating activities | 225 | 141 | 264 | 220 |
| Capital expenditures | 37 | 45 | 46 | 39 |
| Proceeds from sale of property, plant and equipment | - | 0 | 0 | 1 |
| Acquired in-process research and development and milestones | 10 | 20 | 0 | 0 |
| Proceeds from sale of jada | 433 | - | - | - |
| Dermavant acquisition, net of cash acquired | 0 | 0 | 0 | 0 |
| Purchase of product rights and asset acquisition | 0 | 0 | 69 | 0 |
| Net cash flows provided by (used) in investing activities | 386 | -65 | -115 | -38 |
| Proceeds from debt | 0 | 325 | 300 | 340 |
| Repayments of debt | 32 | 507 | 372 | 541 |
| Payment of long-term debt issuance costs | - | 0 | 0 | 0 |
| Employee withholding taxes related to stock-based awards | 1 | 1 | 1 | 12 |
| Dividend payments | 5 | 4 | 3 | 10 |
| Net cash flows used in financing activities | -38 | -187 | -76 | -223 |
| Effect of exchange rate changes on cash and cash equivalents | -31 | 13 | 0 | 93 |
| Net increase (decrease) in cash and cash equivalents | 542 | -98 | 73 | 52 |
| Cash and cash equivalents, beginning of period | 574 | 672 | 599 | 547 |
| Cash and cash equivalents, end of period | 1,116 | 574 | 672 | 599 |
Organon & Co. (OGN)
Organon & Co. (OGN)